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Background: Clinical data that compare external-beam radiotherapy (EBRT) combined with high-dose-rate brachytherapy
(HDR-BT) boost versus EBRT alone are scarce. The analysis of published studies suggest that biochemical relapse-free survival
in combined EBRT and HDR-BT may be superior compared to EBRT alone. We retrospectively examined the effectiveness
and tolerance of both schemes in a single center study.
Methods: Between March 2003 and December 2004, 229 patients were treated for localized T1-T2N0M0 prostate cancer.
Median age was 66 years (range, 49 – 83 years). PSA level ranged from 0.34 to 64 ng/ml (median 12.3 ng/ml) and Gleason
score ranged from 2 to 10. The analysis included 99 patients who underwent EBRT with HDR-BT (group A) and 130 patients
who were treated with EBRT alone (group B).
Results: Median follow-up was 6 years. Biochemical relapses occurred in 34% vs. 22% (p = 0.002), local recurrences in 17%
vs. 5% (p = 0.002), and distant metastases in 11% vs. 6% (p = 0.179) of patients in groups A and B, respectively. Five-year
biochemical relapse-free survival was 67% vs. 81% (p = 0.005), local recurrence-free survival 95% vs. 99% (p = 0.002),
metastases-free survival 95% vs. 94% (p = 0.302) for groups A and B, respectively. Five-year overall survival was 85% in both
groups (p = 0.596). Grade 2/3 late GI complications appeared in 9.2% and 24.8% (p = 0.003), respectively. Grade 2/3 late GU
symptoms occurred in 12% in both groups.
Conclusions: Although because of the retrospective character of the study and nonrandomized selection of fractionation
schedule the present conclusions had limitations EBRT alone appeared more effective than EBRT combined with HDR-BT.
It was likely the result of the less frequent use of androgen deprivation therapy (ADT) for combined scheme group, too low
dose in a single BT fraction or inadequate assumptions regarding fractionation sensitivity of prostate cancer.
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Radical prostatectomy (RP) and radiotherapy are two basic
methods of curative treatment for prostate cancer (PC). Ra-
diation treatment can be conducted using external beam
radiotherapy (EBRT) alone, interstitial brachytherapy (BT)
alone or may combine both of these methods. Comparison
of different treatment methods for early stage prostate
cancer: low-dose-rate BT (LDR-BT), EBRT <72 Gy,
EBRT >72 Gy, combined LDR-BT and RP indicated that
biochemical relapse-free survival (bRFS) was inferior in
low-dose EBRT, compared to the other groups in all
prognostic subsets and was not improved by use of
ADT [1]. A systematic review of treatment methods for
PC by Grimm et al. revealed that the decision on treat-
ment method may depend on risk group. In low-risk
disease BT alone might be the choice, for intermediate-
risk disease the combination of EBRT and BT appears
equivalent to BT alone, for high-risk patients combined
therapies that incorporate EBRT and BT plus or minus an-
drogen deprivation therapy (ADT) appear favorable [2].
Most of the published reports suggest that α/β ratio for
PC is low, PC may be sensitive, thus, to high fractional doses
[3,4]. Hypofractionation enables the application of higher
single fractions in a shorter overall treatment time. This
method is investigational and may be used for EBRT, frac-
tionated stereotactic body radiotherapy and BT [5-8].
Brachytherapy is one of hypofractionated radiotherapy
methods. It can not only shorten the overall treatment
time and limit the geographical miss, but also enables
escalation of the total dose in the target and reduce the
dose in surrounding normal tissues. Permanent or tem-
porary implants are used alone in low-risk (LR) PC pa-
tients or are combined with EBRT in intermediate (IR)
or high-risk (HR) groups [9]. Clinical data that compare
toxicity and efficacy of EBRT combined with HDR-BT
boost and EBRT alone are scarce [10-16].
A systematic review of radiotherapy for PC by Pieters
et al. revealed that the combination of EBRT and HDR-
BT resulted in a better bRFS and OS compared to high-
dose EBRT or EBRT combined with LDR-BT [17].
In this report we retrospectively evaluate the effective-
ness and normal tissue reactions of EBRT combined with
HDR-BT boost in comparison to EBRT alone for PC.
While due to nonrandomized selection of fractionation
schedules such study has apparent limitations it may
provide an interesting insight of the clinical outcomes




Between March 2003 and December 2004, 229 patients
with T1-T2N0M0 PC were treated. The analysis in-
cluded 99 patients who underwent EBRT with HDR-BT(group A) and 130 patients treated with EBRT alone to
the median dose of 74 Gy (group B). The median age of
the group was 66 years (range, 49 – 83 years). Patients
treated with EBRT alone were slightly older than those
treated with the combined scheme (67 vs. 65, p = 0.046
Mann–Whitney U test). All patients had biopsy-proven
adenocarcinoma of the prostate, Gleason score ranged
from 2 to 10. Pretreatment prostate-specific antigen (PSA)
was known in all cases and ranged from 1.7 to 64 ng/ml
(median 12.3 ng/ml). Prior to initiation of treatment, all
patients underwent a complete clinical examination and
laboratory tests (blood count, liver and renal function).
Staging procedures included digital rectal examination
(DRE), transrectal ultrasound (TRUS) of the prostate or
pelvic magnetic resonance imaging. Distant metastases
were excluded by abdomen and pelvis computed tomog-
raphy (CT) or ultrasound examination, chest X-ray and
bone scan. The clinical stage was defined according to
2009 TNM classification system [18]. Patients were di-
vided into risk groups according to D’Amico [19]. The
clinical characteristics of the groups are summarized in
Table 1. In general, the groups were comparable with re-
spect to major prognostic factors, except for use of adju-
vant ADT (further explained below).
The combined treatment was considered in men with
good performance status and with prostate suitable for
TRUS-guided implantation. Patients with a history of trans-
urethral resection or with PC in clinical T3 stage according
to the brachytherapy protocol were excluded. The decision
on treatment method – EBRT alone or combined scheme
was made by patients. They were informed about treatment
methods, all possible complications, the advantages and
disadvantages of the proposed schedules and were given
liberty to choose a preferred therapy.
Androgen deprivation therapy
Neoadjuvant ADT was used in 90% patients in both groups.
Adjuvant ADT was applied in 97 men: 32/99 (32%) in group
A and 65/130 (50%) in group B (p = 0.008 Mann–Whitney
U test). Median duration of ADT in group A was 5.9 months
compared to 12.9 months in group B (p < 0.001 Mann–
Whitney U test). The characteristics of ADT is summarized
in Table 1.
External beam radiotherapy
All patients underwent EBRT with 6–20 MV photons gen-
erated by a linear accelerator. Three-dimensional conformal
planning technique was based on CT in all cases. Patients
were placed in a supine position. Precise and reproducible
patient immobilization was achieved using thermoplastic
mask system (Orfit Industries, Belgium). Clinical target vol-
ume (CTV) included the prostate and base of seminal vesi-
cles, and pelvic lymph nodes in most of HR patients.
Planning target volume (PTV) expansion of 10–15 mm was
Table 1 Characteristics of 229 patients treated with EBRT-BT and EBRT alone for prostate cancer
Characteristics Total Group A EBRT-BT Group B EBRT p (Mann–Whitney U test)
(N =229) (N =99) (N =130)
Age [years] 0.046
Median 66 65 67
Range 49-83 49-83 51-80
Zubrod score 0.1
0 196 (85.6%) 89 (89.9%) 107 (82.3%)
1 32 (14%) 10 (10.1%) 22 (16.9%)
2 1 (0.4%) 0 (0%) 1 (0.8%)
PSA [ng/ml] 0.463
Mean 16.3 15.4 16.9
Median 12.3 11.8 13.9
Range 1.7-64 3.9-56.6 1.7-64
PSA[ng/ml] 0.962
<10 81 (35.4%) 33 (33.3%) 48 (36.9%)
10-20 91 (39.7%) 44 (44.4%) 47 (36.2%)
>20 57 (24.9%) 22 (22.2%) 35 (26.9%)
Gleason score 0.122
2-6 115 (67.7%) 67 (67.7%) 88 (67.7%)
7 39 (17%) 18 (18.2%) 21 (16.2%)
8-10 22 (9.6%) 8 (8.1%) 14 (10.8%)
unknown 13 (5.6%) 6 (6%) 7 (5.3%)
Clinical T stage 0.118
T1b 8 (3.5%) 2 (2%) 6 (4.6%)
T1c 95 (41.7%) 39 (39.4%) 56 (43.1%)
T2a 49 (21.3%) 19 (19.2%) 30 (23.1%)
T2b 26 (11.3%) 12 (12.1%) 14 (10.7%)
T2c 51 (22.2%) 27 (27.3%) 24 (18.5%)
Risk group 0.310
LR 48 (21%) 18 (18.2%) 30 (23.1%)
IR 82 (35.8%) 35 (35.3%) 47 (36.1%)
HR 99 (43.2%) 46 (46.5%) 53 (40.8%)
ADT
Neoadjuvant 206 (90%) 88 (89.8%) 118 (90.7%) 0.639
Adjuvant 97 (42.4%) 32 (32.3%) 65 (50%) 0.008
Salvage 63 (27.4%) 37 (37.4%) 26 (20%) 0.004
no 11 (4.8%) 4 (4%) 7 (5.3%)
Total duration of ADT [months] <0.001
Median 98.9 6 13
Range 0.5-79 0.7-55.6 0.5-79
Whole pelvis EBRT 84 (36.7%) 40 (40.4%) 44 (33.9%) 0.309
PSA nadir [ng/ml] 0.049
Median 0.04 0.07 0.03
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Table 1 Characteristics of 229 patients treated with EBRT-BT and EBRT alone for prostate cancer (Continued)
Range 0-12.3 0-12.3 0-3.1
Time to obtain PSA nadir [months] 0.007
Median 6.3 5.3 8.7
Range 0.9-74.9 1.1-58.4 0.9-74.9
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gans at risk were rectum, urinary bladder, femoral heads and
bowel.
Radiation dose was prescribed and specified in the refer-
ence point according to the guidelines of the International
Commission on Radiation Units Report 50 and 62. Treat-
ment plans were developed with Eclipse treatment-planning
system (Varian Medical System, Palo Alto, CA, USA). Varian
Clinac linear accelerators (Varian Medical System, Palo Alto,
CA, USA) were used in radiation treatment. Portal vision and
in vivo dosimetry were used to control the referral points of
the dosimetric parameters. The final decision on whole pelvis
irradiation depended on risk factors and oncologist’s decision
(40/99 (40.4%) in group A and 44/130 (33.9%) in group B
received pelvic RT). Median external beam dose to the pelvis
was 44 Gy (range, 44–50 Gy) in 22 fractions (range, 22–25
fractions). Median dose to the prostate was 74 Gy (range,
70–76 Gy) in 37 fractions (range, 35–39 fractions) in
group B and 54 Gy (range, 51–56 Gy) in 27 fractions
(range, 27–29 fractions) in group A. The total duration of
radiation treatment in group A was shorter : 34–58 days
(median 41) vs. 41–79 days (median 52) in groups A and
B, respectively.
Brachytherapy
Patients were placed in dorsal lithotomic position under
spinal or general anesthesia. A Foley catheter was used
to fill the urinary bladder with 150 ml of sterile water. A
biplaner TRUS was performed to view the prostate, sem-
inal vesicles, urethra, bladder and rectum and prepare a
preplan. TRUS probe was fixed to the stepper. The en-
tire prostate gland was defined as clinical target volume
(CTV) for HDR-BT. Treatment planning using PLATO
Complete (Nucletron, Veenendaal, The Netherlands) was
performed with the following constraints: maximum dose
to urethra and rectum had to be less than 120% and 7 Gy,
respectively. Needles (from nine to eighteen) were im-
planted under the TRUS guidance. The location of each
needle was visualized and the implant was reconstructed by
the treatment planning system. A single fraction of 10 Gy
was applied by a HDR 192-Ir stepping source unit (Micro-
Selectron™, Nucletron, Veenendaal, The Netherlands).
The dose was calculated on the prostate capsule. A
single-fraction HDR-BT boost was given before, during
or after EBRT. The date of the procedure depended on
patient performance status or waiting time in Brachy-
therapy Department.Follow-up and statistical analysis
Median follow-up time was 6 years (range 0.5–7.6). It
was 5.9 years (range, 0.6 – 7.7 years) and 6 years (range,
1–7.6 years) for EBRT alone and EBRT-BT, respectively.
Patients were evaluated every 3 months during the first
year and every 6 months thereafter. Each evaluation in-
cluded a clinical examination, DRE and PSA concentra-
tion. Acute and late radiation toxicity was evaluated
according to the European Organization for Research
and Treatment of Cancer / Radiation Therapy Oncology
Group (EORTC/RTOG) scoring system [20].
Biochemical failure after RT was defined according to the
Radiation Therapy Oncology Group (RTOG) – American
Society of Therapeutic Radiology and Oncology (ASTRO)
Phoenix consensus criteria: PSA nadir + 2 ng/ml [21]. Local
recurrence was defined as local progression detected by a
biopsy. The biopsy was performed in patients with bioche-
mical relapse and no evidence of distant metastases.
Metastases-free survival (MFS) reflected all distant fail-
ures. Overall survival (OS) reflected all deaths, both cancer
related or not. RFS and bRFS were calculated from the
end of the treatment to the time when any recurrence was
detected or to the last follow-up visit. MFS and OS were
calculated from the beginning of the treatment to a distant
failure, death or the last follow-up visit. The actuarial rates
of bRFS, RFS, MFS and OS were estimated according to
the Kaplan-Meier method. The statistical significance of
the differences between actuarial curves was calculated
using the log-rank test. The Cox proportional hazard re-
gression analysis was applied in the multivariable models.
Student t or Mann–Whitney U tests were applied to test
of the hypothesis that two populations are the same,
against an alternative hypothesis. The difference was con-
sidered significant if the p value was less than 0.05.
Results
PSA nadir
The median nadir value of PSA was lower in group B
compared to group A (0.03 vs. 0.07 ng/ml, p = 0.049
Mann–Whitney U test). The time to obtain PSA nadir in
the group B was significantly longer (8.7 vs. 5.2 months,
p = 0.007 Mann–Whitney U test).
Treatment outcome
At the median follow-up of 6 years, 56/229 (24%) bio-
chemical relapses, 23/229 (10%) local recurrences and 19/
229 (8%) distant metastases occurred in both groups.
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in group A (34/99 (34%) vs. 22/130 (17%) in group B, p =
0.002 Mann–Whitney U test). Local recurrences also oc-
curred more often in group A (17/99 (17%) vs. 6/130 (5%),
p = 0.002 Mann–Whitney U test). Distant metastases ap-
peared in 11/99 (11%) patients in group A and in 8/130
(6%) in group B (p = 0.179, Mann–Whitney U test). The
most common sites of metastases were bones (73%),
lymph nodes (31%), lungs (16%) and the liver (5%).
To date, death occurred in 44/229 (19%) patients in
both groups: 17/99 (17%) died in group A and 27/130
(21%) in group B (p = 0.495, Mann–Whitney U test).
Ten patients (4%) died of prostate cancer: 5/99 (5%) in
group A and 5/130 (4%) in group B (p = 0.659, Mann–
Whitney U test). The remaining 34 patients (15%) died
due to other causes.
The 5-year bRFS rate for group B was 81% and 67%
for group A (p = 0.005, log-rank test) (Figure 1). In the
univariable analysis treatment scheme (p = 0.005) and
risk group (p = 0.041) were significant predictors of the
risk of biochemical failure (Table 2). In the multivariable
Cox proportional hazard regression analysis the treat-
ment scheme (p = 0.016) appeared as an independent
predictor of the risk of biochemical relapse.
The 5-year RFS rate was 99% for group B and 95% for
group A (p = 0.002, log-rank test) (Figure 2). In the uni-
variable analysis treatment schedule (p = 0.002) was
found to be associated with local failure (Table 2). The
multivariable Cox proportional hazard regression ana-
lysis also showed that treatment schedule (p = 0.045) was
associated with higher RFS.
Five-year MFS was 95% and 94% for groups A and B,
respectively (p = 0.302, log-rank test). Five-year OS was
85% in both groups (p = 0.596, log-rank test). The CoxFigure 1 Biochemical relapse-free survival rate according to treatmenproportional hazard regression analysis revealed that risk
group (p = 0.049) was significant for prediction of MFS
and patient’s age (p = 0.038) was significant for predic-
tion of OS. We also estimated the survival within each
risk group. The results are summarized in Table 3.
Side effects
Grade 2 and 3 acute gastrointestinal (GI) symptoms oc-
curred in 18/99 (18.2%) in group A and in 36/130 (27.7%) in
group B (p = 0.094, Mann–Whitney U test). Grade 2 and 3
acute genitourinary (GU) reactions were observed in 42/99
(42.4%) and in 43/130 (33.1%) (p = 0.148, Mann–Whitney U
test), respectively. None of the patients developed grade 4
GI or GU early complications. The most frequent acute re-
actions during radiotherapy were diarrhea of low or
moderate severity and polyuria. Six patients required treat-
ment interruption because of severe diarrhea and paralytic
subileus.
Grade 2 late GI side effects appeared in 9/98 (9.2%)
cases in group A and grade 2 and 3 late GI complications
in 31/125 (24.8%) patients in group B (p = 0.003, Mann–
Whitney U test). No patient developed grade 4 GI late
symptoms. The most frequent late reactions were chronic
diarrhea and intermittent rectal bleedings. Four patients
required the treatment of argon plasma laser coagulation
in group B. Grade 2 and 3 late GU symptoms occurred in
12% in both groups (12/98 in group A and 15/125 in
group B). Urethral strictures and hemorrhagic cystitis
caused a need for catheterization, required endourethral
incisions, transurethral resection of the prostate or electro-
coagulation of teleangiectasis, which appeared in 3/98
(3.1%) in group A and in 5/125 (4%) in group B. No pa-
tient developed grade 4 GU late complications. The
median time interval for occurrence of late GI and GUt schedule. n-number of patients at risk.
Table 2 Variables influencing actuarial rates of bRFS, RFS, MFS, OS
Characteristic 5-y bRFS p 5-y RFS p 5-y MFS p 5-y OS p
Treatment scheme 0.005 0.002 0.302 0.596
EBRT-BT 67 95 95 85
EBRT 81 99 94 85
Age-median 0.452 0.421 0.948 0.029
<66 70 95 95 90
≥66 80 98 94 82
Risk group 0.041 0.894 0.003 0.369
LR 83 97 98 85
IR 81 98 100 88
HR 65 96 88 84
Total duration of ADT [months] 0.089 0.748 0.555 0.156
<9.2 72 100 93 83
≥9.2 78 96 95 86
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fects occurred earlier in patients treated with EBRT
alone.
Discussion
This study compares two radiotherapy schedules: EBRT
combined with HDR-BT and EBRT alone for patients with
PC. After median follow-up time of 6 years, significant dif-
ferences in clinical outcomes were found between the
groups.
The literature data provided by Hoskin et al., Guix et al.,
Zwahlen et al., Kestin et al. [10-14,16] (Table 4) demon-
strated better bRFS after EBRT plus HDR-BT, compared
to EBRT alone. Combination of both modalities may also
improve OS [17]. Such outcome can be explained by highFigure 2 Local recurrence-free survival rate according to treatment scradiation dose that can be prescribed when HDR-BT is
combined with EBRT.
The comparison among the studies presented in Table 4
is difficult due to the apparent differences in the applied
dose of EBRT and HDR-BT schemes, diverse definitions of
risk groups or biochemical failure. However, we noted that
the total dose applied in EBRT alone schedule [10,11,14-16]
was lower (66–70 Gy) than recommended by the current
guidelines. The adequate dose of 76 Gy in EBRT alone
group was applied only in the study by Guix et al. [12,13]
(Table 4).
While because of the retrospective character of the study
and nonrandomized selection of fractionation schedule the
present results have apparent limitations, they suggest
relatively low effectiveness of the combined scheme.hedule. n-number of patients at risk.
Table 3 Five-year survivals according to risk groups and treatment methods
LR group p IR group p HR group p
(N = 48) (N = 82) (N = 99)
5-y bRFS EBRT-BT 77% 0.16 73% 0.06 59% 0.1
EBRT 88% 88% 71%
5-y RFS EBRT-BT 94% 0.07 96% 0.03 94% 0.13
EBRT 100% 100% 100%
5-y MFS EBRT-BT 100% 0.42 100% 0.15 88% 0.98
EBRT 96% 100% 87%
5-y OS EBRT-BT 89% 0.31 88% 0.66 82% 0.72
EBRT 83% 87% 85%
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ing the superiority of the combined therapy. Unexpectedly,
in spite of initial assumptions based on radiobiological
premises i.e.: the prostate tumor’s α/β ratio of 1.5 Gy [22],
the scheme was not even as effective as EBRT alone. One
may postulate that the assumed α/β ratio value for prostate
cancer is not appropriate since some studies suggest is
higher value [23-26], including the studies in which HDR
brachytherapy was used [27].
Notably, Roberts et al. [27] compared bRFS results for
PC patients who received combined EBRT and HDR-BT
with expected projections that were based on dose/frac-
tionation/response parameter values derived from EBRT
alone. Tumor control rates after EBRT and HDR-BT,
were lower in many cases then predicted from linear-
quadratic (LQ) parameter estimates from EBRT alone.
Lower than expected control rates were associated with
BT doses higher than 30 Gy, 1–2 high-dose fractions, 9
fractions (BT alone), doses per fraction of 9–15 Gy, and
treatment in only 1 week. It could be explained by cold




EBRT -BT 35.75Gy/13fx + 2x8.5Gy
EBRT 55Gy/20fx




EBRT -BT 46 Gy/23fx + 3x6Gy or 4x5Gy
EBRT 70 Gy/35fx
Kestin 2000 [16] EBRT + HDR-BT 46 Gy/23fx + 2-3x5.5-10.5Gy
EBRT 66 Gy/33fx
This study (7-year survival) EBRT + HDR-BT 54Gy/27fx + 1x10Gy
EBRT 74Gy/37fx
EQD2 – equivalent total dose in 2-Gy fractions.applicability of the LQ model at high doses per fraction
[27]. This study supports our findings, that a combined
scheme of one high-dose BT fraction of 10 Gy may pro-
vide biochemical and local control lower than expected.
Relatively small total dose in combined BT and EBRT
used in the present study may also contribute to the un-
satisfactory local effectiveness. In some studies BT was
administered in the minimum of 2 fractions that allowed
to escalate the dose, limit the toxicity and avoid the risk
of nonhomogenous dose distribution (Table 4). On the
other hand, escalation of EBRT dose with one BT frac-
tion may appear effective, as shown by Agoston et al.
[28] or Boladeras et al. [29].
Another factor contributing to the observed outcome
could be the difference in use of hormone treatment in
the analyzed groups: adjuvant ADT was more often ap-
plied in the EBRT alone than in the group treated with
the combined method (50% vs. 32%, p = 0.008). The total
time of the applied ADT was also longer in the EBRT
alone (12.9 vs. 5.9 months, p < 0.001). In Agoston et al.
and Boladeras et al. studies that show a favorablestate cancer
EQD2 α/β = 1.5 Gy EQD2 α/β = 3 Gy 5-year bRFS 5-year OS
92 Gy 80.21 Gy 75% (66%) 88% (81%)
66.8 Gy 63.25 Gy 61% (48%) 89% (81%)
89.4 Gy 81.2 Gy IR HR -
97% 96%
76 Gy 76 Gy 90% 89% -
82.1-84.6 Gy 78-78.4 Gy 82.5% (80.3%) 91.9% (89.5%)
70 Gy 70 Gy 81.3% (71%) 88.7% (86.2%)
79-118 Gy 74.1-102.7 Gy 67% -
66 Gy 66 Gy 44% -
86.8 Gy 80 Gy 67% (59%) 85% (80%)
74 Gy 74 Gy 81% (76%) 85% (73%)
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companied by long adjuvant ADT in most of the patients
[28,29].
At last, we note that the bRFS rate in the EBRT alone
group in the present study compares favorably to bRFS
rates in some published studies on a high-dose radiotherapy
[30,31].
The majority of studies on radiotherapy in prostate can-
cer assessed not only the effectiveness of treatment but
also its tolerance. Comparing the toxicity in diverse stud-
ies is difficult due to different classifications of radiation
reactions or by reporting the incidence of severe side ef-
fects only. According to the published studies, acute GU
reactions were more intense in the combined scheme
groups [8,14,16]. By contrast, late GI reactions more often
appeared in EBRT alone groups [12,13]. Late GU side ef-
fects were comparable in both groups [10-13,15]. A
similar outcome has been presented in this analysis. In
general, the treatment was well tolerated in both groups.
Conclusions
Although because of the retrospective character of the
study and nonrandomized selection of fractionation sched-
ule the present conclusions had limitations, EBRT alone
appeared more effective than EBRT combined with HDR-
BT. It was likely the result of the less frequent use of an-
drogen deprivation therapy in combined scheme group,
too low dose in a single BT fraction or inadequate assump-
tions regarding fractionation sensitivity of prostate cancer.
Acute and late GI complications were more severe in the
group treated with EBRT alone. Acute GU symptoms were
more intense in the EBRT with HDR-BT group, late GU
reactions were comparable in both groups.
Abbreviations
ADT: Androgen deprivation therapy; ASTRO: American Society of Therapeutic
Radiology and Oncology; bRFS: Biochemical relapse-free survival; BT: Brachytherapy;
CT: Computed tomography; CTV: Clinical target volume; DRE: Digital rectal
examination; EBRT: External beam radiotherapy; EORTC: European Organization for
Research and Treatment of Cancer; EQD2: Equivalent total dose in 2-Gy fractions;
Fx: Fraction; Gy: Gray; HDR-BT: High-dose-rate brachytherapy boost; HR: High-risk;
IR: Intermediate-risk; LDR: Low-dose-rate; LQ: Linear-quadratic; LR: Low-risk;
MFS: Metastases-free survival; OS: Overall survival; PC: Prostate cancer; PSA: Prostate
specific antigen; PTV: Planning target volume; RFS: Recurrence-free survival;
RP: Radical prostatectomy; RTOG: Radiation Therapy Oncology Group;
SBRT: Stereotactic body radiotherapy; TRUS: Transrectal ultrasound.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
BSC participated in design of the study, collected clinical data, prepared
statistical analysis, interpreted the data and prepared draft of the manuscript.
LM participated in design of the study, was involved in revision of the
manuscript and interpretation of the data. BB was involved in revision of the
manuscript. MF helped to collect clinical data. GP helped to collect clinical
data. MGS was involved in revision of the manuscript. MG helped to collect
clinical data. KB helped in statistical analysis. EN helped to collect clinical
data. AZ was involved in revision of the manuscript. RS participated in study
design, was involved in drafting of the manuscript and its revision. All
authors read and approved the final manuscript.Received: 20 November 2014 Accepted: 20 February 2015
References
1. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al.
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam
radiotherapy ≥72 Gy, permanent seed implantation, or combined seeds/
external beam radiotherapy for stage T1–T2 prostate cancer. Int J Radiat
Oncol Biol Phys. 2004;58:25–33.
2. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, et al.
Comparative analysis of prostate-specific antigen free survival outcomes for
patients with low, intermediate and high risk prostate cancer treatment by
radical therapy. Results from the Prostate Cancer Results Study Group. BJU
Int. 2012;109 Suppl 1:22–9.
3. Miralbell R, Roberts SA, Zubizarreta E, Hendry JH. Dose-fractionation sensitivity
of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in
seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat
Oncol Biol Phys. 2012;82:e17–24.
4. Dasu A. Is the alpha/beta value for prostate tumours low enough to be
safely used in clinical trials? Clin Oncol. 2007;19:289–301.
5. Pollack A, Walker G, Buyyounouski M, Horwitz E, Price R, Feigenberg S, et al.
Five year results of a randomized external beam radiotherapy
hypofractionation trial for prostate cancer. Int J Radiat Oncol Biol Phys.
2011;81 Suppl 1:S1.
6. Kuban DA, Noguaras-Gonzalez GM, Hamblin L, Lee AK, Choi S, Frank SJ, et al.
Preliminaary report of a randomized dose escalation trial for prostate cancer
using hypofractionation. Int J Radiat Oncol Biol Phys. 2010;78 Suppl 1:S58–9.
7. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al.
Stereotactic body radiotherapy for localized prostate cancer: pooled analysis
from a multi-institutional consortium of prospective phase II trials. Radiat
Oncol. 2013;109:217–21.
8. Prada PJ, Gonzales H, Fernandez J, Jiménez I, Iglesias A, Romo I. Biochemical
outcome after high-dose-rate intensity modulated brachytherapy with
external beam radiotherapy: 12 years of experience. BJU Int. 2011;7:1–7.
9. Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA,
et al. GEC/ESTRO recommendations on high dose rate afterloading
brachytherapy for localised prostate cancer: an update. Radiother Oncol.
2013;107:325–32.
10. Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate
brachytherapy in combination with external beam radiotherapy in the
radical treatment of prostate cancer: initial results of a randomised phase
three trial. Radiother Oncol. 2007;84:114–20.
11. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised
trial of external beam radiotherapy alone Or combined with high-dose-rate
brachytherapy boost for localised prostate cancer. Radiother Oncol.
2012;103:217–22.
12. Guix B, Bartina J, Tello J, Henriquez I, Quinzaños L, Lacorte T, et al. Dose
escalation with high-dose 3D-conformal radiotherapy (HD-3D-CRT) or
low-dose 3D-conformal radiotherapy plus HDR brachytherapy (LD-3D-CRT +
HDR-B) for intermediate- or high-risk prostate cancer: higher PSA control
with lower toxicity [abstract]. Urology. 2011;78(Suppl):S23.
13. Guix B, Bartina J, Tello J, Solé J, Quinzaños L, Lacorte T, et al. Treatment of
intermediate- or high-risk prostate cancer by dose escalation with high-dose
3D-conformal radiotherapy (HD-3D-CRT) or low-dose 3D-conformal radiotherapy
plus HDR brachytherapy (LD-3D-CRT +HDR-B) for: early results of a prospective
comparative trial [abstract]. Int J Radiat Oncol Biol Phys. 2010;78 Suppl 1:S78.
14. Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL.
High-dose-rate brachytherapy with conformal external beam radiotherapy
in the treatment of prostate cancer. Brachytherapy. 2010;9:27–35.
15. Sathya JR, Davis IR, Julian JA, Guo Q, Daya D, Dayes IS, et al. Randomized
trial comparing iridium implant plus external-beam radiation therapy with
external-beam radiation therapy alone in node-negative locally advanced
cancer of the prostate. JCO. 2005;23:1192–9.
16. Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS,
Brabbins DS, et al. Matched-pair analysis of conformal high-dose-rate
brachytherapy boost versus external-beam radiation therapy alone for
locally advanced prostate cancer. J Clin Oncol. 2000;18:2869–80.
17. Pieters BR, de Back DZ, Koning CC, Zwinderman AH. Comparison of three
radiotherapy modalities on biochemical control and overall survival for the
treatment of prostate cancer: a systematic reviev. Radiother Oncol.
2009;93:168–73.
Smolska-Ciszewska et al. Radiation Oncology  (2015) 10:60 Page 9 of 918. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti 3rd A, editors.
Cancer staging AJCC. 7th ed. New York: Springer; 2010.
19. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA,
et al. Biochemical outcome after radical prostatectomy, external beam
radiation therapy, or interstitial radiation therapy for clinically localized
prostate cancer. JAMA. 1998;280:969–74.
20. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Oncology Group
(RTOG) and European Organization for Research and Treatment of Cancer
(EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–6.
21. Roach 3rd M, Hanks G, Thames Jr H, Schellhammer P, Shipley WU, Sokol GH,
et al. Defining biochemical failure following radiotherapy with or without
hormonal therapy in men with clinically localized prostate cancer:
recommendations of the RTOG-ASTRO phoenix consensus conference.
Int J Radiat Oncol Biol Phys. 2006;65:965–74.
22. Fijałkowski M, Białas B, Maciejewski B, Bystrzycka J, Ślusarek K. Three-dimensional
(3d) real-time conformal brachytherapy – a novel solution for prosatae cancer
treatment. Part II. A feasibility clinical pilot study. Nowotwory, journal of. Oncology.
2005;55:115–21.
23. Kal HB, Van Gellekom MPR. How low is the α/β ratio for prostate cancer?
Int J Radiat Oncol Biol Phys. 2003;57:1116–21.
24. Nickers P, Hermesse J, Daneufbourg JM, Vanbelle S, Lartigau E. Which α/β
ratio and half-time of repair are useful for predicting outcomes in prostate
cancer? Radiather Oncol. 2010;97:462–6.
25. Shaffer R, Pickles T, Lee R, Moiseenko V. Deriving prostate alpha-beta ratio
using carefully matched groups, long follow-Up and the phoenix definition
of biochemical failure. Int J Radiat Oncol Biol Phys. 2011;79:1029–36.
26. Nahum AE, Movsas B, Horwitz EM, Stobbe CC, Chapman JD. Incorporating
clinical measurements of hypoxia into tumor local control modeling of
prostate cancer: Implications for the a/b ratio. Int J Radiat Oncol Biol Phys.
2003;57:391–401.
27. Roberts SA, Miralbell R, Zubizarreta EH, Fowler JF, Hendry JH. A modelled
comparison of prostate cancer control rates after high-dose-rate brachytherapy
(3145 multicentre patients) combined with, or in contrast to, external-beam
radiotherapy. Radiather Oncol. 2014;111:114–9.
28. Agoston P, Major T, Frohlich G, Szabó Z, Lövey J, Fodor J, et al. Moderate
dose escalation with single-fraction high-dose rate brachytherapy boost for
clinically localized intermediate- and high-risk prostate cancer: 5-year
outcome of the first 100 consecutively treated patients. Brachytherapy.
2011;10:376–84.
29. Boladeras A, Santorsa L, Gutierrez C, Martinez E, Pera J, Pino F, et al. External
beam radiotherapy plus single-fraction high dose rate brachytherapy in the
treatment of locally advanced prostate cancer. Radiather Oncol.
2014;112:227–32.
30. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, et al.
Escalated-dose versus standard-dose conformal radiotherapy in prostate
cancer: first results from the MRC RT01 randomised controlled trial. Lancet
Oncology. 2007;8:475–87.
31. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al.
Randomized trial comparing conventional-dose with high-dose conformal
radiation therapy in early stage adenocarcinoma of the prostate: long-term
results from proton radiation oncology group/american college of radiology
95–09. J Clin Oncol. 2010;28:1106–11.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
